Fasting content treats these two words as interchangeable. They aren't, and the distinction has practical consequences — because the compounds that induce one do not reliably induce the other.
If you're buying supplements for "cellular cleanup," this is the difference between hitting the target and missing it.
Autophagy: The General Recycling System
Autophagy — literally "self-eating" — is how a cell disassembles its own damaged components and reuses the parts. Misfolded proteins, worn-out organelles, protein aggregates: a double-membrane structure called an autophagosome engulfs the debris and fuses with a lysosome, where enzymes break it down into amino acids and fatty acids the cell can re-spend.
Yoshinori Ohsumi won the 2016 Nobel Prize in Physiology or Medicine for mapping the mechanism.
It matters for ageing because autophagic capacity declines with age while cellular damage accumulates — a widening gap between mess made and mess cleared. In post-mitotic tissue like neurons and cardiac muscle, cells cannot dilute damage by dividing. Autophagy is their only option.
Mitophagy: The Specialist Subsidiary
Mitophagy is selective autophagy targeting mitochondria specifically. It's a subset — but a subset with its own dedicated machinery, and that's the crux.
When a mitochondrion is damaged, it loses membrane potential. A kinase called PINK1, normally imported and degraded, accumulates on the outer membrane of the depolarised organelle. PINK1 recruits and activates Parkin, which tags the mitochondrion with ubiquitin, flagging it for autophagosome capture.
Why mitochondria warrant a dedicated system: a damaged mitochondrion is not merely useless, it is actively dangerous. It leaks reactive oxygen species and can release cytochrome c, triggering apoptosis. Broken mitochondria damage the cells housing them, which is why their removal is prioritised.
The Practical Difference
| Autophagy | Mitophagy | |
|---|---|---|
| Target | Any damaged component | Damaged mitochondria only |
| Selectivity | Largely non-selective | Highly selective |
| Key machinery | mTOR, AMPK, ATG genes | PINK1/Parkin, receptors |
| Main triggers | Fasting, exercise, caloric restriction | Membrane depolarisation, exercise |
| Studied compounds | Spermidine, resveratrol, fisetin | Urolithin A, NAD⁺ precursors |
| Failure looks like | Aggregate accumulation, senescence | Falling ATP, rising oxidative stress |
Here's the part worth underlining: inducing general autophagy does not guarantee adequate mitophagy. The PINK1/Parkin pathway has its own regulation and its own age-related decline. A protocol built entirely around spermidine and fasting can leave mitochondrial quality control under-addressed.
Compounds Studied for Autophagy
Spermidine
The best-characterised dietary autophagy inducer. Eisenberg and colleagues (2009), in Nature Cell Biology, demonstrated spermidine induces autophagy and extends lifespan in yeast, flies, nematodes and human immune cells. Preclinical Kiechl and colleagues (2018) then reported, in a large prospective human cohort, that higher dietary spermidine intake was associated with lower all-cause mortality. Human observational
The form matters. Wheat germ extract is the common cheap source and delivers variable, low spermidine content. Spermidine 3HCl is the stabilised trihydrochloride salt — a defined quantity rather than a plant extract with a hopeful label.
Fisetin
Fisetin is classed as a senolytic rather than a pure autophagy inducer — it targets senescent cells, which have stopped dividing but refuse to die and secrete inflammatory signals. Yousefzadeh and colleagues (2018), in EBioMedicine, found fisetin reduced senescent cell burden and extended both median and maximum lifespan in mice, including when started late in life. Preclinical Human senolytic trials are ongoing; results are not yet published.
Trans-resveratrol
Trans-Resveratrol activates SIRT1 and AMPK, both upstream regulators of autophagy. Timmers and colleagues (2011), in Cell Metabolism, gave resveratrol to obese men for 30 days and observed metabolic changes resembling caloric restriction, including reduced liver fat and improved muscle mitochondrial function. Human trial, small
Compounds Studied for Mitophagy
Urolithin A
The clearest mitophagy story in the supplement space. Urolithin A is a gut metabolite of ellagitannins — most people don't produce it, because it depends on gut bacteria only a minority carry.
Andreux and colleagues (2019), in Nature Metabolism, published a first-in-human randomised trial showing oral Urolithin A was safe and induced a mitophagy-associated gene expression signature in human skeletal muscle. Human trial Singh and colleagues (2022) followed with a four-month randomised trial in JAMA Network Open reporting improved muscle endurance in middle-aged adults. Human trial
That's an unusually strong evidence position for this category: mechanism confirmed in human tissue, plus a functional outcome in a controlled trial.
NAD⁺ precursors and the PINK1/Parkin pathway
Mitophagy is NAD⁺-dependent — sirtuins, particularly SIRT3 in the mitochondrial matrix, require NAD⁺ to function. As NAD⁺ falls with age, mitophagic capacity falls with it, which is one mechanistic argument for pairing NMNH or NMN with a direct mitophagy inducer rather than choosing between them. Mechanism
How to Cover Both
A protocol addressing only one system leaves the other unaddressed. Practically:
- General autophagy — spermidine, plus the strongest non-supplement lever available: sustained fasting windows and resistance training.
- Mitophagy — Urolithin A, supported by adequate NAD⁺.
- Senescent cell burden — fisetin, on the understanding that human trials are still in progress.
The Longevity Complex™ covers the autophagy and NAD⁺ arms in one formulation. Urolithin A and fisetin are available separately for anyone building the cleanup side out further.
Browse autophagy & mitophagy compounds →References
Eisenberg T, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009;11(11):1305–1314. Preclinical
Kiechl S, et al. Higher spermidine intake is linked to lower mortality. Am J Clin Nutr. 2018;108(2):371–380. Human observational
Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1:595–603. Human trial
Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28. Preclinical
These statements have not been evaluated by the Food and Drug Administration. Not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before use.
